The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.
Toyama Chemical concludes Exclusive License Agreement with Cempra for development, manufacturing and commercialization of its novel macrolide antibiotic “Solithromycin”
|May 14, 2013|
Toyama Chemical Co., Ltd. (Headquarters: Tokyo, Japan; President: Masuji Sugata, “Toyama Chemical”), a subsidiary of FUJIFILM Holdings Corporation, announced today that, on May 8, it signed an exclusive license agreement with Cempra, Inc. (Headquarters: NC, US; President: Prabhavathi Fernandes, “Cempra”) to develop, manufacture and commercialize solithromycin, a macrolide antibiotic originally discovered by the company, in Japan.
Solithromycin shows potent antibacterial effect against pneumococcal and Mycoplasma isolates which are resistant to macrolides on the market, as well as fairly high immunomodulating (anti-inflammatory) effect. A phase 2 study of oral form in US has demonstrated an efficacy against respiratory tract infections and a phase 3 study in patients with community-acquired pneumonia is underway in US and Europe since December 2012.
Toyama Chemical signed an agreement with Cempra for development, manufacturing and commercialization of solithromycin in Japan and will begin clinical studies with the aim of submitting marketing application within five years. Toyama Chemical will pay an upfront of $10 million to Cempra.
In Japan, there is a great need for new macrolide antibiotics on the background of decreasing number of new drug candidates for oral antibiotics. Toyama Chemical has developed penicillin, cephem and quinolone antibiotics and, by adding a macrolide to them, will increase its lineup of drugs in an anti-infective field.
Toyama Chemical, a subsidiary of FUJIFILM Holdings Corporation, specializes in pharmaceutical research and development, and strives to “contribute to the further development of global health care through new drug development”.